# Targeting the astrocytic metabolic cascade in Alzheimer’s disease: mechanisms, challenges and opportunities

## TL;DR

This paper explores how metabolic changes in astrocytes contribute to Alzheimer's disease and suggests targeting these changes as a potential treatment approach.

## Contribution

The paper introduces a conceptual model of 'astrocyte-centric metabolic collapse' as a core driver of Alzheimer's disease.

## Key findings

- Astrocytic metabolic dysregulation disrupts energy homeostasis and accelerates synaptic degeneration in Alzheimer's.
- Metabolic derailment in astrocytes amplifies Aβ and tau pathologies and neuroinflammation.
- Therapeutic strategies targeting astrocytic metabolism are evaluated for their potential in Alzheimer's treatment.

## Abstract

Alzheimer’s disease (AD), a pressing global public health challenge, is underpinned by multifaceted pathogenic mechanisms. While traditional research has centered on amyloid-β deposition and tau hyperphosphorylation, emerging evidence reveals that metabolic perturbations play a pivotal role in the earliest phases of AD. As the principal regulators of energy homeostasis within the central nervous system, astrocytes orchestrate a multistep metabolic cascade—encompassing glucose uptake, glycolysis, mitochondrial oxidative metabolism, and the release of metabolic intermediates—to sustain neuronal energy supply and synaptic integrity. In the AD milieu, this astrocytic metabolic cascade becomes profoundly disrupted at every level. Such metabolic dysregulation not only compromises the neuroprotective functions of astrocytes but also directly accelerates synaptic degeneration, exacerbates Aβ and tau pathologies, and amplifies neuroinflammatory responses, collectively forming a core “metabolic-neurodegeneration” pathological axis. Here, we provide a comprehensive synthesis of the aberrant astrocytic metabolic cascade in AD, delineating its critical contributions to synaptic deterioration, proteinopathy progression, and inflammatory escalation. Building on these insights, we propose a conceptual model of an “astrocyte-centric metabolic collapse,” highlighting metabolic derailment as a fundamental initiating and amplifying force in AD pathogenesis. Furthermore, we evaluate therapeutic strategies targeting key nodes of this cascade and discuss the challenges and opportunities inherent in modulating astrocytic metabolism. Through integrating the most recent advances, this review offers a refined understanding of astrocytic metabolic dysregulation in AD and examines its potential as a promising avenue for therapeutic intervention.